Table 1. Clinical data and outcomes of the two groups.

	AED group (n = 44)	No AED group (n = 40)	p value
Age (mean ± SD)	52.8 ± 12.7	52.4 ± 13.9	0.906
Gender			0.835
Male	21 (47.7%)	20 (50.0%)
Female	23 (52.3%)	20 (50.0%)
AED			NA
Levetiracetam	Valproic acid	NA
Valproic acid	9 (20.5%)	NA
Underlying disease			0.673
HTN	9 (20.5%)	8 (20.0%)
DM	3 (6.8%)	3 (7.5%)
Dyslipidemia	6 (13.6%)	4 (10.0%)
Smoking	8 (18.2%)	6 (15.0%)
Aneurysm location			0.104
ICA	10 (22.7%)	11 (27.5%)
ACA	15 (34.1%)	10 (25.0%)
MCA	17 (38.6%)	9 (22.5%)
Posterior circulation	2 (4.5%)	10 (25.0%)
Aneurysm shape			0.032
Saccular	44 (100%)	36 (90.0%)
Dissecting	0 (0%)	4 (10.0%)
Aneurysm size (mm, mean ± SD)	6.32 ± 2.94	7.65 ± 5.59	0.177
Initial HHG			0.990
1	1 (2.3%)	0 (0.0%)
2	29 (65.9%)	22 (55.0%)
3	18 (40.9%)	14 (35.0%)
Fisher grade			0.980
1	0 (0.0%)	0 (0.0%)
2	7 (15.9%)	7 (17.5%)
3	29 (65.9%)	26 (65.0%)
4	8 (18.2%)	7 (17.5%)
EVD or Shunt	9 (20.5%)	5 (12.5%)	0.298
Hydrocephalus	10 (22.7%)	4 (10%)	0.254
Symptomatic vasospasm	7 (15.9%)	5 (12.5%)	0.772
Procedure related complication	3 (6.8%)	1 (2.5%)	0.621
Systemic complication	9 (20.5%)	2 (5.0%)	0.106
Treatment modality			< 0.001
Microsurgery	37 (84.1%)	7 (17.5%)
Endovascular surgery	7 (15.9%)	33 (82.5%)
Clinical outcome at discharge			0.607
Favorable (mRS 0~2)	38 (86.4%)	36 (90.0%)
Poor (mRS 3~6)	6 (13.6%)	4 (10.0%)
Clinical outcome on 6-month			0.178
Favorable (mRS 0~2)	38 (86.4%)	38 (95.0%)
Poor (mRS 3~6)	6 (13.6%)	2 (5.0%)

ACA = anterior cerebral artery; AED = antiepileptic drug; DM = diabetes mellitus; EVD = external ventricular drainage; HTN = hypertension; ICA = internal carotid artery; MCA = middle cerebral artery; NA = not applicable; mRS = modified Rankin Scale; SD = standard deviation